Denali Therapeutics is advancing the fight against neurodegenerative diseases thanks to pioneering work in methods to carry ...

Key to 400-employee Denali's submission is the FDA allowing measurement of a type of GAG, called heparan sulfate, in ...

After some high-profile crashes, the one-time biotech darling is inching toward success with its Hunter syndrome treatment, ...

Denali Therapeutics, Inc. (NASDAQ:DNLI) shares traded higher on Wednesday after the company initiated its biologics license application (BLA) for the accelerated approval of Tividenofusp Alfa for the ...

Denali Therapeutics (DNLI) announced that the company’s initiation of a rolling submission of a biologics license application, BLA, for ...

Protagonist (Nasdaq: PTGX) is one of a handful of Bay Area drug developers ready to ask the Food and Drug Administration to ...

Thrivent Financial for Lutherans reduced its stake in Denali Therapeutics Inc. (NASDAQ:DNLI – Free Report) by 33.0% in the ...

AlphaQuest LLC increased its stake in Denali Therapeutics Inc. (NASDAQ:DNLI – Free Report) by 177.1% in the fourth quarter, according to the company in its most recent disclosure with the SEC. The ...

Despite past failures, Denali's extensive pipeline and solid financial runway make it a compelling buy at current low stock ...

Denali Therapeutics’ amyotrophic lateral sclerosis (ALS) drug has racked up another clinical miss this year, leaving the company to mull the asset’s future. The therapy, dubbed DNL343 ...